|
GSK news
|
GlaxoSmithKline is a leading healthcare company that helps people to do more, feel better and live longer. This RSS feed contains press releases and investor news.
|
-
GSK statement on tender offer to acquire Human Genome Sciences
GlaxoSmithKline plc (LSE: GSK) today commented on Human Genome Sciences (NASDAQ: HGSI) Board of Directors’ decision to recommend against GSK’s tender offer to acquire all of the outstanding shares of HGS for US$13.00 per share in cash. The offer represents a premium of 81 percent to HGS’s closing share price of US$7.17 on 18th April, the last trading day before HGS publicly disclosed GSK’s private offer. The offer is not conditioned on due diligence or financing.
-
GlaxoSmithKline completes transaction to increase its ownership in Theravance
GlaxoSmithKline plc (“GSK”) (LSE:GSK) and Theravance, Inc. (“Theravance”) (NASDAQ: THRX) announced today that following approval by Theravance, Inc.‟s stockholders at their Annual Meeting held on 15 May 2012, and expiration of applicable waiting periods under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976, GSK‟s acquisition of 10,000,000 shares of Theravance common stock on the terms previously announced on 2 April 2012, has now completed.
-
GlaxoSmithKline to fully acquire Cellzome for £61 million
GlaxoSmithKline plc (GSK) today announced that it has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US$99 million) in cash. Cellzome, a privately owned company with laboratories in Cambridge, UK, and Heidelberg, Germany, will become part of GSK’s R&D organisation.
-
GSK statement on BBC Panorama broadcast: ‘the truth about tax’
GSK statement on BBC Panorama broadcast: ‘the truth about tax’
-
Stiefel receives US FDA approval of Fabior™ Foam, 0.1%
Stiefel, a GSK (NYSE:GSK) company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%.
-
GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
-
GSK to commence tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
GSK announced that it will not participate in Human Genome Sciences strategic alternatives review process and will instead commence a tender offer this week to acquire all of the outstanding shares of HGS for US$13.00 per share in cash.
-
James Shannon named GlaxoSmithKline Chief Medical Officer
James Shannon has been named GSK's Chief Medical Officer (CMO), effective 1 May. James will report to R&D Chairman Moncef Slaoui and be based in London. He will be accountable for medical governance and patient safety for all of GSK: Pharmaceuticals, Consumer Healthcare, Vaccines and the global businesses.
-
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board
-
GlaxoSmithKline and Yale University establish drug discovery collaboration to design potential new class of medicines
GlaxoSmithKline and Yale University establish drug discovery collaboration to design potential new class of medicines
|
